The Global Biosimilars Partnering Agreements 2014-2019 report provides an understanding and access to the biosimilars partnering deals and agreements entered into by the worlds leading healthcare companies.
The Global Biosimilars Partnering Terms and Agreements 2014-2019 report provides an understanding and access to the biosimilars partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter biosimilarspartnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors biosimilarstechnology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
This report provides details of the latest biosimilars, oligonucletides including aptamers agreements announced in the healthcare sectors.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of all biosimilars partnering deals announced since 2014 including financial terms where available including over 500 links to online deal records of actual biosimilars partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
For example, analyzing actual company deals and agreements allows assessment of the following:
The initial chapters of this report provide an orientation of biosimilars dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in biosimilars dealmaking since 2014, including details of average headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading biosimilars deals since 2014. Deals are listed by headline value, signed by big pharma, most active biosimilars dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in biosimilars dealmaking with a brief summary followed by a comprehensive listing of biosimilars deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 5 provides a comprehensive and detailed review of biosimilars partnering deals signed and announced since Jan 2014, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Chapter 6 lists biosimilars/biobetters deals by technology type.
Chapter 7 provides a comprehensive and detailed review of biosimilars partnering deals signed and announced since Jan 2014. The chapter is organized by specific biosimilars technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided organized by biosimilars partnering company A-Z, deal type definitions and biosimilars partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in biosimilars partnering and dealmaking since 2014.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of biosimilars technologies and products.
Global Biosimilars Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to biosimilars trends and structure of deals entered into by leading companies worldwide.
Global Biosimilars Partnering Terms and Agreements includes:
In Global Biosimilars Partnering Terms and Agreements, the available contracts are listed by:
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Table of Content
Chapter 1 – Introduction
Chapter 2 – Trends in biosimilars dealmaking
2.2. Biosimilars partnering over the years
2.3. Most active biosimilars dealmakers
2.4. Biosimilars partnering by deal type
2.5. Biosimilars partnering by therapy area
2.6. Deal terms for biosimilars partnering
2.6.1 Biosimilars partnering headline values
2.6.2 Biosimilars deal upfront payments
2.6.3 Biosimilars deal milestone payments
2.6.4 Biosimilars royalty rates
Chapter 3 – Leading biosimilars deals
3.2. Top biosimilars deals by value
Chapter 4 – Most active biosimilars dealmakers
4.2. Most active biosimilars dealmakers
4.3. Most active biosimilars partnering company profiles
Chapter 5 – Biosimilars contracts dealmaking directory
5.2. Biosimilars contracts dealmaking directory
Chapter 6 – Biosimilars dealmaking by technology type
Chapter 7 – Partnering resource center
7.1. Online partnering
8.2. Partnering events
8.3. Further reading on dealmaking
Appendix 1 – Biosimilars deals by company A-Z
Appendix 2 – Biosimilars deals by stage of development
Appendix 3 – Biosimilars deals by deal type
Appendix 4 – Biosimilars deals by therapy area
Central Nervous System
Appendix 5 –Deal type definitions
About Wildwood Ventures
Recent report titles from Current Partnering
Figure 1: Biosimilars partnering since 2014
Figure 2: Active biosimilars dealmaking activity since 2014
Figure 3: Biosimilars partnering by deal type since 2014
Figure 4: Biosimilars partnering by disease type since 2014
Figure 5: Biosimilars deals with a headline value
Figure 6: Biosimilars deals with an upfront value
Figure 7: Biosimilars deals with a milestone value
Figure 8: Biosimilars deals with a royalty rate value
Figure 9: Top biosimilars deals by value since 2014
Figure 10: Most active biosimilars dealmakers since 2014
Figure 11: Online partnering resources
Figure 12: Forthcoming partnering events
Make an enquiry before buying this Report
Please fill the enquiry form below.